wilate®
von Willebrand Factor/Coagulation Factor VIII Complex (Human)

Updated wilate® reconstitution with the convenient and easy-to-use nextaro® transfer device[1-5,a]



Preparing for reconstitution with nextaro® is simple[1]

- wilate® may be refrigerated[b] for up to 36 months or stored for up to 6 months at room temperature.[c] Do not freeze wilate®.
- If stored below room temperature, warm both closed vials by using a warm water bath or rubbing the vials between your hands.[d]
- Inspect all components for physical integrity prior to use. Do not use products or components that appear damaged or broken.
- Reconstitute wilate® in a clean environment and minimize contamination.
- Only reconstitute the powder immediately before injection and use the solution within 4 hours.

Please click here to contact your local Patient Experience Manager with any questions

[a]In a usability study, nextaro® was preferred over Mix2Vial® by healthcare professionals in a clinical setting.[3]
[b]36°F to 46°F (2°C to 8°C).
[c]Not to exceed 77°F (25°C).
[d]If a water bath is used for warming, avoid water contact with the rubber stoppers of the vial caps. The temperature of the water bath should not exceed 98°F (37°C).

Indications and Important Safety Information for wilate® [von Willebrand Factor/Coagulation Factor VIII Complex (Human)].

Indications
wilate® is a von Willebrand Factor/Coagulation Factor VIII Complex (Human) indicated in adult and pediatric patients with von Willebrand disease for on-demand treatment and control of bleeding episodes; for perioperative management of bleeding; and for routine prophylaxis to reduce the frequency of bleeding episodes. wilate® is also indicated in adult and pediatric patients 12 years of age and older with hemophilia A for on-demand treatment and control of bleeding episodes; and for routine prophylaxis to reduce the frequency of bleeding episodes.

Contraindications
Do not use in patients with known hypersensitivity reactions, including anaphylactic or severe systemic reaction, to human plasma-derived products, any ingredient in the formulation, or components of the container.

Please click here for Full Prescribing Information.

wilate®
von Willebrand Factor/Coagulation Factor VIII Complex (Human)

Reconstitution Is Simple[1]



Step 1

Prepare the vials

Remove the caps from the wilate® concentrate vial and water vial and clean the rubber stoppers with an alcohol swab.



Step 2

Open nextaro®

Open the nextaro® transfer device package by peeling off the lid.

Leave the nextaro® device in the clear outer packaging and avoid touching the device to keep it clean.



Step 3

Attach nextaro® to the water vial

Hold the water vial firmly on a hard, level surface. With nextaro® still in the outer packaging, turn it upside down and **push the blue part straight and firmly down on the water vial** until it snaps into place.

Do not twist while attaching.

Note: nextaro® must be attached to the water vial first. Otherwise, there will be a loss of suction, and the water will not flow into the wilate® vial.



Step 4

Attach the wilate® vial

Carefully remove the outer package from the nextaro® transfer device.

With the wilate® vial held firmly on a hard, level surface, flip the water vial with the attached transfer device upside down and **secure the white part of the transfer device to the wilate® vial by pressing on it until it snaps into place.**

The water will be drawn into the wilate® vial by the vacuum.



Step 5

Swirl the connected vials

With both vials still attached, immediately start to **gently swirl** the connected vials to ensure that the powder is fully saturated.

Do not shake.



Step 6

Detach nextaro®

After swirling for 30 seconds, firmly hold the white and blue parts of the nextaro® transfer device. Unscrew nextaro® counterclockwise into two separate pieces.

Discard the empty water vial and blue part of the transfer device.



Step 7

Continue swirling

Without touching the connector, continue swirling the wilate® vial until the powder has fully dissolved. This process may take several minutes.

The final solution is clear or slightly opalescent, colorless, or slightly yellow. Reconstituted products should be inspected visually for particulate matter.



Step 8

Prepare for infusion

Use a syringe to draw out the reconstituted product.

Do not use if the powder fails to dissolve or any solids are formed.

Use/infuse wilate® as directed.

Dispose of sharps in their designated location.

Important Safety Information (cont'd)

Warnings and Precautions

- Anaphylaxis and severe hypersensitivity reactions are possible
- Thromboembolic events may occur. Monitor plasma levels of FVIII activity
- Neutralizing antibodies (inhibitors) to VWF and Factor VIII have occurred following administration of wilate®. Test for neutralizing antibodies if plasma VWF and/or Factor VIII level fail to increase as expected or if bleeding is not controlled after wilate® administration
- wilate® is made from human plasma and carries the risk of transmitting infectious agents

Adverse Reactions

The most common adverse reactions (≥1%) in clinical trials on VWD were hypersensitivity reactions, urticaria, chest discomfort, and dizziness. The most common adverse reaction (≥1%) in clinical trials in hemophilia A was pyrexia (fever).

Please click here for Full Prescribing Information.

References: 1. wilate Full Prescribing Information. Paramus, NJ: Octapharma; rev 2026. **2.** US Food and Drug Administration. 510K Summary: K183187. March 2019. Accessed October 15, 2026. https://www.accessdata.fda.gov/cdrh_docs/pdf18/K183187.pdf **3.** Data on File, Octapharma 2023. **4.** Evolution of transfer systems. sfm medical devices GmbH. Published June 16, 2021. https://www.nextaro.com/en/blog/read/evolution-of-transfer-systems.html **5.** Sustainability and environmental protection through innovative medical products. sfm medical devices GmbH. Published May 15, 2023. https://www.nextaro.com/en/blog/read/sustainability-and-environmental-protection-through-innovative-medical-products.html

© 2026 Octapharma USA, Inc. All rights reserved.
Date of preparation: 10/2026. WIL-0833
nextaro is a registered trademark of sfm medical devices GmbH.
Mix2Vial is a registered trademark of West Pharma. Services IL, Ltd., a subsidiary of West Pharmaceutical Services, Inc.

octapharma